Skip to main content
Quest Diagnostics

Biomarker Testing in Alzheimer’s Disease

Learning Objectives:

  -  Gain understanding of dementia and the laboratory tests used fo help evaluate

     these patients

  -  Know how amyloid, tau and neurodegeneration participate in Alzheimer's

     Disease

  -  Gain understanding of how biomakers and PET are used to evaluate Alzheimer's

     Disease

 

Presented by: Michael K. Racke, MD, Medical Director of Neurology, Quest Diagnostics  

 

Moderated by: Gabriele Olla, Dir Product Management , Neurology, Quest Diagnostics

Date:
Sep 29, 2021
Location:
Biomarker Testing in Alzheimer's Disease on-demand webinar
Presenter(s):
Michael K. Racke, MD
Moderator(s):
Gabriele Olla

Related content

On-Demand Webinar
Revolutionizing Alzheimer’s Disease Clinical Trials Using a Blood-Based Diagnostic Test for Participant Identification
On-Demand Webinar
Assessing Alzheimer's Disease Risk in Primary Care Settings
Audio Podcast
Alzheimer’s disease: A new generation of screenings and therapies on the horizon
Audio Podcast
Patient-minded Neurology
Publication
The small HDL particle hypothesis of Alzheimer's disease
On-Demand Webinar
Revolutionizing Alzheimer’s Disease Clinical Trials Using a Blood-Based Diagnostic Test for Participant Identification

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.